Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

Mark Cragg's Biography

Mark Cragg, Professor and Chair in Experimental Cancer Biology, Centre for Cancer Immunology, University of Southampton, Southampton General Hospital

Mark Cragg is Professor of Experimental Cancer Biology in the Cancer Sciences Unit of Southampton University Faculty of Medicine. His research focuses on understanding two main types of therapeutics – antibodies and small molecule inhibitors. Over the last decade, he has investigated many different therapeutic reagents such as rituximab, bexxar, imatinib, gefitinib, cetuximab and tarceva and has been involved in the development of next generation antibody reagents such as ofatumumab and obinutuzumab, as well as first in class novel antibodies such as BI-1206.

He has published >140 papers in reputed journals and is a member of several advisory and editorial boards.

Mark Cragg Image

Determinants of Antibody Immunotherapy

Monday, 28 October 2019 at 10:30

Add to Calendar ▼2019-10-28 10:30:002019-10-28 11:30:00Europe/LondonDeterminants of Antibody ImmunotherapyImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The

There is growing appreciation of the depth of interaction between tumour cells and their surrounding microenvironment. These interactions augment tumour growth, proliferation and mediate immune suppression. Of critical importance is how these interactions affect antibody immunotherapy and how they might be targeted to improve treatment efficacy. This presentation will discuss several key determinants of antibody immunotherapy.

Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The